欧洲罕见疾病基因检测市场：分析与预测（2023-2033）

欧洲罕见疾病基因检测市场规模预计将从 2023 年的 11.6 亿美元增至 2033 年的 41.7 亿美元，预测期内复合年增长率为 13.60%。

由于对早期检测这些疾病的需求不断增加，罕见疾病基因检测市场正在经历显着成长。罕见疾病发生率的增加是这一增长轨蹟的关键因素。此外，人们对早期检测和预防的认识和兴趣日益增强，特别是在全球儿童人群中，预计这将进一步推动市场成长。

本报告调查了欧洲罕见疾病基因检测市场，并提供了市场概况、主要趋势、法律制度、专利趋势、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场和国家。我们分别编製了详细的报告分析、主要企业简介等

市场分类：

细分 1：依疾病类型

• 消化系统疾病
• 内分泌/代谢疾病
• 心血管疾病
• 神经系统疾病
• 血液/肿瘤疾病
• 皮肤科疾病
• 其他的

细分 2：依技术分类

• Sanger定序
• PCR
• NGS
• 微阵列
• 其他（标靶细胞遗传学、核型分析、FISH）

细分 3：按国家/地区

• 德国
• 英国
• 法国
• 义大利
• 俄罗斯
• 西班牙
• 其他的

主要企业：

• CENTOGENE NV
• Eurofins Scientific SE
• QIAGEN NV

目录

执行摘要

调查范围

第一章 市场

• 全球市场展望
  • 产品定义
  • 纳入与排除标准
  • 市场概况
  • COVID-19 对市场的影响
• 产业分析
  • 法律规范
  • 专利分析
  • 资金筹措场景
• 市场动态
  • 概述
  • 市场驱动因素
  • 市场挑战
  • 市场机会

第二章 欧洲

• 欧洲罕见疾病基因检测市场
  • 市场动态
  • 市场规模/预测

第三章 公司简介

Introduction to Europe Rare Disease Genetic Testing Market

The Europe rare disease genetic testing market was valued at $1.16 billion in 2023 and is anticipated to reach $4.17 billion by 2033, witnessing a CAGR of 13.60% during the forecast period 2023-2033. The market for genetic testing in rare diseases has experienced notable growth, driven by a rising need for early identification of such conditions. The growing occurrence of rare diseases has been a pivotal factor in this growth trajectory. Moreover, there's a heightened acknowledgment and focus on early detection and prevention, particularly among pediatric populations worldwide, which is anticipated to further drive market growth.

Market Introduction

The Europe rare disease genetic testing market in Europe is witnessing substantial growth driven by several factors. Increasing awareness and advancements in genetic testing technologies have propelled demand for early detection and diagnosis of rare diseases across the continent. Additionally, the rising prevalence of rare diseases in European populations has contributed significantly to market growth. Moreover, there's a growing emphasis on early intervention and personalized medicine, further boosting the adoption of genetic testing for rare diseases. Regulatory initiatives and healthcare policies promoting accessibility to genetic testing services also play a crucial role in market development. As healthcare systems in Europe prioritize precision medicine and improved patient outcomes, the rare disease genetic testing market is poised for continued growth, offering opportunities for innovation and collaboration among stakeholders in the healthcare sector.

Market Segmentation:

Segmentation 1: by Disease Type

• Gastroenterology Disease
• Endocrine and Metabolism Disease
• Cardiovascular Disease
• Neurology Disease
• Hematology and Oncology Disease
• Dermatology Disease
• Other Diseases

Segmentation 2: by Technology

• Sanger Sequencing
• PCR
• NGS
• Microarrays
• Others (Targeted Cytogenetics, Karyotyping, and FISH)

Segmentation 3: by Country

• Germany
• U.K.
• France
• Italy
• Russia
• Spain
• Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The rare disease genetic testing market has been extensively segmented based on various categories, such as disease type, technology, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Competitive Strategy: The rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

• CENTOGENE N.V.
• Eurofins Scientific SE
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Market

• 1.1 Global Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.2.1 Inclusion Criteria
    • 1.1.2.2 Exclusion Criteria
  • 1.1.3 Market Overview
    • 1.1.3.1 Market Footprint
    • 1.1.3.2 Market Size and Future Growth Potential
  • 1.1.4 COVID-19 Impact on the Market
    • 1.1.4.1 Impact on Research and Clinical Operations
    • 1.1.4.2 COVID-19 Impact: Current Scenario of the Market
• 1.2 Industry Analysis
  • 1.2.1 Regulatory Framework
    • 1.2.1.1 Legal Requirements and Framework in the U.S.
    • 1.2.1.2 Legal Requirements and Framework in Europe
      • 1.2.1.2.1 U.K.
      • 1.2.1.2.2 Spain
    • 1.2.1.3 Legal Requirements and Framework in Asia-Pacific
      • 1.2.1.3.1 Japan
      • 1.2.1.3.2 China
      • 1.2.1.3.3 India
      • 1.2.1.3.4 Taiwan
  • 1.2.2 Patent Analysis
    • 1.2.2.1 Patent Filing Trend (by Country)
    • 1.2.2.2 Patent Filing Trend (by Year)
  • 1.2.3 Funding Scenario
• 1.3 Market Dynamics
  • 1.3.1 Overview
  • 1.3.2 Market Drivers
    • 1.3.2.1 Rapid Technological Advancements in Rare Disease Diagnosis
    • 1.3.2.2 Rising Prevalence of Genetic Disorders and Congenital Disorders
    • 1.3.2.3 Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Pediatric Populations
  • 1.3.3 Market Challenges
    • 1.3.3.1 Lack of Consolidation of Information Leading to Difficulty in Diagnosis
    • 1.3.3.2 Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Whole Genome Sequencing Putting an End to the Rare Disease Genetic Testing Odysseys
    • 1.3.4.2 AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses
    • 1.3.4.3 Transitioning toward Increased Genetics Coverage in Reimbursement Policies

2 Europe

• 2.1 Europe Rare Disease Genetic Testing Market
  • 2.1.1 Market Dynamics
    • 2.1.1.1 Impact Analysis
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 Europe Rare Disease Genetic Testing Market (by Disease Type)
    • 2.1.2.2 Europe Rare Disease Genetic Testing Market (by Technology)
    • 2.1.2.3 Europe Rare Disease Genetic Testing Market (by Country)
      • 2.1.2.3.1 Germany
        • 2.1.2.3.1.1 Market Dynamics
        • 2.1.2.3.1.2 Market Size and Forecast
        • 2.1.2.3.1.2.1 Germany Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.1.2.2 Germany Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.2 U.K.
        • 2.1.2.3.2.1 Market Dynamics
        • 2.1.2.3.2.2 Market Size and Forecast
        • 2.1.2.3.2.2.1 U.K Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.2.2.2 U.K. Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.3 France
        • 2.1.2.3.3.1 Market Dynamics
        • 2.1.2.3.3.2 Market Size and Forecast
        • 2.1.2.3.3.2.1 France Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.3.2.2 France Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.4 Italy
        • 2.1.2.3.4.1 Market Dynamics
        • 2.1.2.3.4.2 Market Size and Forecast
        • 2.1.2.3.4.2.1 Italy Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.4.2.2 Italy Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.5 Spain
        • 2.1.2.3.5.1 Market Dynamics
        • 2.1.2.3.5.2 Market Size and Forecast
        • 2.1.2.3.5.2.1 Spain Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.5.2.2 Spain Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.6 Russia
        • 2.1.2.3.6.1 Market Dynamics
        • 2.1.2.3.6.2 Market Size and Forecast
        • 2.1.2.3.6.2.1 Russia Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.6.2.2 Russia Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.7 Rest-of-Europe
        • 2.1.2.3.7.1 Market Dynamics
        • 2.1.2.3.7.2 Market Size and Forecast
        • 2.1.2.3.7.2.1 Rest-of-Europe Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.7.2.2 Rest-of-Europe Rare Disease Genetic Testing Market (by Technology)

3 Company Profiles

• 3.1 Overview
  • 3.1.1 CENTOGENE N.V.
    • 3.1.1.1 Company Overview
    • 3.1.1.2 Role of CENTOGENE N.V. in the Rare Disease Genetic Testing Market
    • 3.1.1.3 Financials
    • 3.1.1.4 Recent Developments
    • 3.1.1.5 Analyst Perspective
  • 3.1.2 Eurofins Scientific SE
    • 3.1.2.1 Company Overview
    • 3.1.2.2 Role of Eurofins Scientific SE in the Rare Disease Genetic Testing Market
    • 3.1.2.3 Financials
    • 3.1.2.4 Recent Developments
    • 3.1.2.5 Analyst Perspective
  • 3.1.3 QIAGEN N.V.
    • 3.1.3.1 Company Overview
    • 3.1.3.2 Role of QIAGEN N.V. in the Rare Disease Genetic Testing Market
    • 3.1.3.3 Financials
    • 3.1.3.4 Recent Developments
    • 3.1.3.5 Analyst Perspective

List of Figures

• Figure 1: Global Prevalence Rare Disease, 2022
• Figure 2: Europe Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 3: Europe Rare Disease Genetic Testing Market, Market Dynamics
• Figure 4: Most Frequently Studied Rare Diseases, 2021
• Figure 5: Europe Rare Disease Genetic Testing Market Share (by Technology), 2022 and 2033
• Figure 6: Europe Rare Disease Genetic Testing Market Share (by Disease Type), 2022 and 2033
• Figure 7: Rare Disease Genetic Testing Market (by Region), $Billion, 2022 and 2033
• Figure 8: Share of Key Developments and Strategies, January 2019-June 2023
• Figure 9: Rare Disease Genetic Testing Market: Research Methodology
• Figure 10: Primary Research Methodology
• Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 12: Top-Down Approach (Segment-Wise Analysis)
• Figure 13: Europe Rare Disease Genetic Testing Market Potential, $Billion, 2022-2033
• Figure 14: Regulatory Scenario in Europe (by Country)
• Figure 15: Rare Disease Genetic Testing Market, Patent Analysis (by Country), January 2018- June 2023
• Figure 16: Rare Disease Genetic Testing Market, Patent Analysis (by Year), January 2018-June 2023
• Figure 17: NIH Funding on Rare Diseases, $Million, 2013-2023
• Figure 18: Rare Disease Genetic Testing Market Dynamics
• Figure 19: Rare Disease Prevalence in India, 2022
• Figure 20: Global Prevalence of Rare Diseases, 2022
• Figure 21: Most Frequently Studied Rare Diseases, 2021
• Figure 22: Publications Related to the Use of Artificial Intelligence for Rare Disease Diagnosis, 2015-2022
• Figure 23: Rare Disease Genetic Testing Market Share (by Region), 2022-2033
• Figure 24: Europe Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 25: Europe Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 26: Europe Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 27: Europe Rare Disease Genetic Testing Market (by Country), % Share, 2022 and 2033
• Figure 28: Germany Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 29: Germany Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 30: Germany Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 31: U.K. Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 32: U.K. Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 33: U.K. Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 34: France Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 35: France Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 36: France Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 37: Italy Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 38: Italy Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 39: Italy Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 40: Spain Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 41: Spain Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 42: Spain Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 43: Russia Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 44: Russia Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 45: Russia Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 46: Rest-of-Europe Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 47: Rest-of-Europe Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 48: Rest-of-Europe Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 49: Rare Disease Genetic Testing Market, Total Number of Key Companies Profiled
• Figure 50: CENTOGENE N.V.: Product Portfolio
• Figure 51: CENTOGENE N.V.: Overall Financials, $Million, 2020-2022
• Figure 52: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2020-2022
• Figure 53: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2020-2022
• Figure 54: CENTOGENE N.V.: R&D Expenditure, $Million, 2020-202
• Figure 55: Eurofins Scientific SE: Product Portfolio
• Figure 56: Eurofins Scientific SE: Overall Financials, $Million, 2020-2022
• Figure 57: Eurofins Scientific SE: Net Revenue (by Segment), $Million, 2020-2022
• Figure 58: Eurofins Scientific SE: Net Revenue (by Region), $Million, 2020-2022
• Figure 59: QIAGEN N.V.: Product Portfolio
• Figure 60: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
• Figure 61: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
• Figure 62: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
• Figure 63: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Funding for Rare Disease Research
• Table 3: Technological Advancements in the Rare Disease Genetic Testing Ecosystem
• Table 4: Expansion of Medicare Coverage for Rare Disease Genetic Testing Tests (by Companies)
• Table 5: Europe Rare Disease Genetic Testing Market, Impact Analysis